Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections

Cardiovascular diseases (CVDs) and complications are often seen in patients with prostate cancer (PCa) and affect their clinical management. Despite acceptable safety profiles and patient compliance, androgen deprivation therapy (ADT), the mainstay of PCa treatment and chemotherapy, has increased cardiovascular risks and metabolic syndromes in patients. A growing body of evidence also suggests that patients with pre-existing cardiovascular conditions show an increased incidence of PCa and present with fatal forms of the disease. Therefore, it is possible that a molecular link exists between the two diseases, which has not yet been unraveled. This article provides insight into the connection between PCa and CVDs. In this context, we present our findings linking PCa progression with patients' cardiovascular health by performing a comprehensive gene expression study, gene set enrichment (GSEA) and biological pathway analysis using publicly available data extracted from patients with advanced metastatic PCa. We also discuss the common androgen deprivation strategies and CVDs most frequently reported in PCa patients and present evidence from various clinical trials that suggest that therapy induces CVD in PCa patients.

Automated summary

Cardiovascular diseases (CVDs) and complications are commonly observed in patients with prostate cancer (PCa) and can impact their clinical management. Androgen deprivation therapy (ADT), the main treatment for PCa, has been shown to increase cardiovascular risks and metabolic syndromes. There is emerging evidence of a molecular link between PCa and CVDs, but it remains to be fully understood. This article explores the connection between PCa and CVDs, utilizing a comprehensive gene expression study and biological pathway analysis.